Kornimate/medical-research-clean huggingface dataset:
the effects of kinesio taping on pain, range of motion, and functional performance in people with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the goal of this clinical trial is to evaluate the effectiveness of kinesio taping in individuals with knee osteoarthritis (koa). koa is a common condition that can lead to pain, stiffness, and decreased mobility. the main questions it aims to answer are: * does kinesio taping reduce pain in individuals with koa? * can kinesio taping improve the range of motion and functional performance in those suffering from koa? participants will be asked to: attend assessment sessions at the outpatient physical therapy clinic at taibah university. undergo kinesio taping three times over 12 days. complete specific physical tests and questionnaires before and after the intervention period to measure their pain and mobility. researchers will compare the group that receives kinesio taping with the group that receives sham (placebo) taping to see if there are significant differences in pain reduction and improvements in movement and daily function.

study overview this clinical trial explores kinesio taping's (kt) effect on knee osteoarthritis (koa) in adults. it delves into whether kt can alleviate pain and improve joint movement and daily functioning. the research, hosted at taibah university's physical therapy clinic, focuses on practical benefits for patients with koa, a condition that leads to significant discomfort and mobility issues, especially prevalent in saudi arabia. study design in a randomized and single-blinded approach, participants are divided into two groups. one group receives actual kinesio taping, while the other undergoes a sham procedure, with neither group aware of their specific treatment type to ensure unbiased results. intervention procedures participants undergo three kinesio taping sessions spread over 12 days. the taping technique is performed according to prescribed methods that target the quadriceps femoris muscle, believed to influence pain perception and joint function positively. the study employs a before-and-after intervention assessment model. initial data collection includes patients' demographic details and baseline characteristics related to their health status and disease severity. following the intervention, the same measures are reassessed to evaluate any changes attributed to the kt.

Eligibility criteria:
inclusion criteria: * patients clinically and radiologically diagnosed with unilateral or bilateral knee oa. * independent gait * any grade on the kellgren-lawrence scale exclusion criteria: * previous fractures of the femur and/or tibia. * comorbidities such as neurological diseases, malnutrition, and other inflammatory and/or infectious diseases. * radicular pain in the lower limbs or diabetic neuritis. * prior physiotherapy in the past month.
a pilot study to investigate the efficacy of partially absorbable mesh in patients with pelvic organ prolapsed

Conditions: Pelvic Organ Prolapse

Summary: the purpose of this study is to evaluate the efficacy, recurrence, postoperative complications of partially absorbable mesh(seratom®pa) in patients with pelvic organ prolapse.

patients with pelvic organ prolapse are administrated partially absorbable mesh(seratom®pa). it is performed pelvic organ prolapse quantification(pop-q) examination, quality of life(qol) questionnaire complications at postop 2week, 12week, 24week.

Eligibility criteria:
inclusion criteria: 1. woman who aged 41 years or older 2. subjects who have symptomatic pelvic organ prolapse quantification(pop-q) stage ii \& cystocele or higher requiring surgical repair 3. subjects who desires vaginal reconstructive surgery 4. subjects who have uterus \< 12 weeks size 5. subjects who are able to complete study questionnaires and assessment 6. subjects who are available for 6 months follow-up exclusion criteria: 1. subjects who have medical contractions, e.g. current urinary tract, vaginal or pelvic infection, history of pelvic irradiation, history of lower urinary tract malignancy, chronic steroid use, or a compromised immune system 2. subjects who have received anticoagulation therapy 3. subjects who are on current intermittent catheterization 4. subjects whose bmi is over 30kg/m2 5. subjects who have uncontrolled diabetes 6. subjects who are on any medication which could result in compromised immune response, such as immune modulators 7. subjects who are currently pregnant or intends to become pregnant during the study period or \<12 months post-partum 8. subjects who have received other laparoscopic or abdominal or pelvic surgery in the past 1 months 9. subjects who need for concomitant surgery requiring an abdominal incision 10. subjects who have had a prior prolapse implant procedure (i.e. ivs tunneler, perigee, apogee, graft augmented repair, etc) * note: previous traditional repairs are allowed. 11. subjects who have had radiation therapy to the pelvic area 12. subjects who have pelvic cancer or have had pelvic cancer within the past 12 months or have had on cytostatic medication within the past 12 months 13. subjects who have a shortened vagina or other known mullerian anomaly (e.g. uterine didelphys.) 14. subjects who have a known neurologic or medical condition affecting bladder function (e.g. multiple sclerosis, spinal cord injury) 15. subjects who have a known hypersensitivity to the graft material(s)

Keywords: partially absorbable mesh
study to evaluate efficacy and safety of jtt-251 in participants with pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: study to evaluate the efficacy, safety, tolerability and pharmacokinetics of jtt-251 administered for 24 weeks in participants with pulmonary arterial hypertension (pah)

this is a study to evaluate the efficacy, safety, tolerability and pharmacokinetics of jtt-251 administered for 24 weeks in participants with pulmonary arterial hypertension (pah). participants completing this study (relief-pah) will be eligible to enroll in an open-label extension study (relief-pah ole) to evaluate the long-term efficacy, safety, tolerability and pharmacokinetics of jtt-251 in participants with pah.

Eligibility criteria:
inclusion criteria: * diagnosis of pah as classified by idiopathic, heritable, drug and toxin- induced, congenital heart disease or associated with connective tissue disease (i.e., who group 1) * clinical diagnosis of pah confirmed by rhc at any time prior to visit 1 * who functional status of class ii-iv at visit 1 * two 6mwd test measurements between 100 and 450 meters with a relative difference of ≤15%. the baseline 6mwd test must be performed at visit 2 before randomization. * have a qualifying rhc performed between visit 1 and visit 2 * on stable dose(s) of guideline-directed medical therapy for pah (endothelin receptor antagonists, phosphodiesterase type-5 (pde-5) inhibitors, soluble guanylate cyclase stimulators and prostacyclin pathway analogs) for at least 90 days prior to the qualifying rhc exclusion criteria: * pah associated with portal hypertension, human immunodeficiency virus (hiv), schistosomiasis or sickle cell disease as well as participants with pulmonary parenchymal disease or thromboembolic disease * known significant left heart disease including: left ventricular dysfunction (i.e., left ventricular ejection fraction \<35%); hemodynamically compromising, symptomatic, or severe aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation * pulmonary hypertension belonging to who groups 2 to 5 * moderate to severe obstructive lung disease defined as forced expiratory volume in 1 second (fev1) \<55% of predicted value * moderate to severe restrictive lung disease defined as total lung capacity (tlc) \<60% of predicted value * acute decompensated heart failure or hospital admission for worsening pah symptoms within 30 days prior to the qualifying rhc

Keywords: jtt-251 pulmonary arterial hypertension relief-pah six-minute walk distance (6mwd)
effects of online yoga on the quality of life of breast cancer patients

Conditions: Breast Neoplasms; Cancer

Summary: this study investigates the effects of two different online yoga interventions on the health-related quality of life in breast cancer patients. qualitative and quantitative data will be collected.

in this randomized controlled trial breast cancer patients will be randomized into three treatment arms: * intervention group 1 will receive an iyengar yoga intervention online in a group setting, based on the internationally renowned yoga school of b.k.s. iyengar, which in the context of this study mainly includes physical and relaxation exercises. * intervention group 2 will receive a meditative yoga intervention online including physical and meditation exercises and also ideologically neutral explanations of the ethical aspects of yoga. * group 3 consists of a waiting list control group, combined with the offer to participate in a yoga intervention after 4 months.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of non-metastatic breast cancer (tnm stage i-iii) up to 5 years after diagnosis * primary therapy completed for at least 3 months * limitation of the quality of life due to the cancer (indication of at least 4 out of 10 points on the numerical analogue scale) * willingness to participate in the study and signed informed consent. exclusion criteria: * current or planned chemotherapy, radiation or surgery * severe physical or psychopharmacologically treated psychiatric comorbidity due to which a patient is unable to participate in the study * pregnancy/breastfeeding * participation in other clinical trials with behavioral, psychological, or complementary medicine interventions * immobility or limitation for gymnastic exercise due to orthopedic, neurologic, or other medical cause * regular meditation practice \>2x/month * regular yoga practice \>2x/month

Keywords: yoga
safety and efficacy of mt-4666

Conditions: Alzheimer's Disease

Summary: the objective of this study is to evaluate the safety and efficacy as assessed by the alzheimers disease assessment scale-cognitive subscale 13-item (adas-cog-13) of two doses of mt-4666 or placebo administered daily for 24 weeks to subjects with mild to moderate alzheimer's disease.


Eligibility criteria:
inclusion criteria: * probable alzheimer's disease consistent with national institute of neurological and communicative disorders and stroke (nincds) and alzheimer's disease and related disorders association (adrda) criteria * mmse score of 10 to 24 inclusive at screening and at day 1, and cdr-sb score of ≥ 2 at screening * modified hachinski ischemic score (mhis) ≤ 4 at screening * caregiver available; caregiver sees subject at least four days (at least 12 hours) each week * subject living at home; if living at senior residential setting, or an institutional setting, subject with caregiver indicated above is available exclusion criteria: * inability to perform cognitive tests (adas-cog-13 and mmse) at screening and at day 1 * diagnosis of any other disease which may cause dementia * mri or ct scan within 6 months before screening, with findings inconsistent with the diagnosis of probable ad * diagnosis of major depressive disorder as defined by diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) within last five years * history of or current diagnosis of any psychosis * history of myocardial infarction or unstable angina within six months before screening * history of cerebrovascular disorder within 18 months before screening

Keywords: alzheimer's disease nicotinic acetylcholine receptor agonist cognitive function dementia central nervous system agents
masked comparison of a new peg based artificial tear and optive for comfort, vision & wear time in patients wearing contact lenses

Conditions: Comfort, Vision and Wear Time

Summary: the objective of this study is to evaluate the effect of a new peg based artificial tear as compared to optive on comfort, wear time, and vision in patients wearing contact lenses.


Eligibility criteria:
inclusion criteria: * use of soft contact lenses (e.g. silicone hydrogel lenses, daily disposables etc.) and multipurpose solution for cleaning, including enzyme-based cleaners (clearcare etc.) * able to wear contact lenses for approximately 10-12 hours/day * willingness to complete entire length of trial and comply with subjective questionnaire. exclusion criteria: * patients taking topical cyclosporine (restasis) * patients currently using optive for dryness relief. * patients wearing hard or rigid gas permeable lenses * patients with uncontrolled systemic disease which may confound the results of the trial.
the fish and fruit study: trial of fish and fruit to improve survival of aboriginal people with end stage renal disease

Conditions: Cardiovascular Diseases

Summary: cardiovascular disease is the main cause of death in patients on dialysis for end stage renal disease. omega-3 fatty acids and antioxidants have been shown to be protective in the general population. a diet of fish and fruit, which will provide the fatty acids and the antioxidants is being tried in dialysis patients to assess the effect on cardiovascular disease in this high risk group.

end stage renal disease (esrd) is a devastating disease which affects aboriginal australians disproportionately: the average survival time for aboriginal people in the northern territory is 3.6 years from the onset of kidney failure, compared to 12.3 years for non-aboriginal people. there has been a dramatic rise in incidence of kidney failure over the past 20 years, with the prevalence doubling every 4-5 years in many nt communities and other remote parts of australia. mortality for patients with esrd is approximately 5 to 10 fold that of the general population, with heart disease accounting for approximately half of deaths. the aims of this study are to determine whether a dietary intervention of fish and fruit three times a week will decrease cardiovascular and all-cause mortality in patients on haemodialysis in darwin and alice springs . there is a strong scientific rationale for this simple dietary intervention. fish are a rich source of omega-3 fatty acids, believed to reduce the risk of heart attack. fruit is a good source of anti oxidants and other chemicals that may amplify the beneficial effects of fish. participants are randomized to either control and intervention groups according to their regular days of dialysis. nutritional and cardiovascular status will be measured at commencement of the study and then at intervals of 3, 6 and 12 months. strategies have been incorporated into the project design to ensure understanding, informed consent and participation of aboriginal people in a number of domains: the participant, their family, urban and remote communities, and service providers. if successful this intervention will result in changes to the clinical management of renal patients worldwide.

Eligibility criteria:
inclusion criteria: * all patients on hemodialysis exclusion criteria: * malignancy

Keywords: dialysis omega-3 fatty acids antioxidants cardiovascular markers mortality end-stage renal disease
a study to evaluate mavacamten impact on myocardial structure in participants with symptomatic obstructive hypertrophic cardiomyopathy

Conditions: Cardiomyopathy, Hypertrophic

Summary: the purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (cmr) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (ohcm) \[new york heart association (nyha) functional class ii or iii\].


Eligibility criteria:
inclusion criteria * diagnosed with obstructive hypertrophic cardiomyopathy (ohcm), in accordance with current american college of cardiology foundation/american heart association and european society of cardiology guidelines as below:. * left ventricular outflow tract (lvot) peak gradient ≥ 30 mmhg and ≥ 50 mmhg after valsalva or after exercise. * left ventricular ejection fraction (lvef) ≥ 55% at rest. * new york heart association (nyha) functional class ii or iii symptoms. exclusion criteria * a known infiltrative or storage disorder causing cardiac hypertrophy that mimics ohcm. * documented obstructive coronary artery disease or history of myocardial infarction. * a history of resuscitated sudden cardiac arrest or life-threatening ventricular arrhythmia within 6 months prior to screening. * an implantable cardioverter defibrillator (icd) or pacemaker, or another contraindication for cardiac magnetic resonance imaging (cmr). * other protocol-defined inclusion/exclusion criteria apply.

Keywords: bms-986427 myk-461 mavacamten obstructive hypertrophic cardiomyopathy (ohcm) camyzos cardiac magnetic resonance imaging (cmr)
immunogenicity and safety study of allantoic split inactivated seasonal influenza vaccine (vsi)

Conditions: Influenza

Summary: the study is a single centre, phase ii, double-blind, randomized, comparative trial that explored the immunogenicity and safety of single dose a allantoic split inactivated seasonal influenza vaccine and vaxigrip vacccine in healthy adults the two age groups (in persons 18 to 60 years of age and older than 60 years).


Eligibility criteria:
inclusion criteria: * volunteers (men and women) aged 18 years and older. * literate and willing to provide written informed consent. * a signed informed consent. exclusion criteria: * available in anamnaze volunteer at any allergic reactions. * allergic reactions to chicken proteins, or any preceding vaccination. * acute illness with a fever (37.0 c). * vaccination against influenza in the 2015/2016 season. * current or recent (within two weeks of enrollment) acute respiratory illness with or without fever. * hypersensitivity after previous administration of any vaccine. * history of chronic alcohol abuse and/or illegal drug use. * any clinically significant abnormal laboratory finding. * a positive pregnancy test for all women of childbearing potential. * administration of immunosuppressive drugs or other immune modifying drugs within 4 weeks prior to study enrollment. * acute or chronic clinically significant pulmonary disease, cardiovascular disease, gastrointestinal disease, liver disease, neurological illness, liver disease, blood disease, skin disorder, endocrine disorder, neurological illness and psychiatric disorder as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives. * history of leukemia or any other blood or solid organ cancer. * receipt of antivirals, antibiotics, immunoglobulins or other blood products within 4 weeks prior to study enrollment or planned receipt of such products during the period of subject participation in the study. * participation in another clinical trial within the previous three months or planned enrollment in such a trial during the period of this study. * subjects who are, in the opinion of the investigator, at significantly increased risk of non-cooperation with requirements of the study protocol.

Keywords: phase ii split vaccine
lactobacillus-containing cultured milk drink alleviates depression score among adults with irritable bowel syndrome

Conditions: Irritable Bowel Syndrome With Subthreshold Depression

Summary: irritable bowel syndrome (ibs) is frequently associated with any form of psychiatric comorbidities including subthreshold or subclinical depression. modification of gut ecology with probiotics has implicitly improved ibs and depressive symptoms. however, the efficacy of probiotics on ibs with existing subthreshold depression remain elusive. therefore, the aim of this study is to evaluate the effects of lactobacillus-containing cultured milk drink on depression scores in adults diagnosed with ibs.

a total of 140 subjects who fulfilled rome iv criteria for ibs will be recruited from a tertiary medical centre and among public volunteers. the depression status and categories will be assessed using the centre epidemiologic studies depression scale revised questionnaire (cesd-r): normal mood (score\ 16). the subjects are randomised and blinded into four groups: group a (normal mood with placebo, n=35), group b (normal mood with probiotics, n=35), group c (subthreshold depression with placebo, n=35) and group d (subthreshold depression with probiotics, n=35). the subjects will be instructed to consume two bottles of cultured milk drink daily for 12 weeks. the probiotic cultured milk drinks contained 10\^9 cfu l. casei-01 and la-5. the severity of depression will be measured using patient health questionnaire (phq-9) at pre- and post-12-week intervention. secondary outcome on ibs symptoms severity will be assessed with ibs symptoms severity score (ibs-sss) and ibs quality of life (ibs-qol).

Eligibility criteria:
inclusion criteria: * aged 18 to 65 years old, * meet rome iv criteria for irritable bowel syndrome, * consented to participate in the study. exclusion criteria: * lactose intolerance, * gastrointestinal disorders such as inflammatory bowel diseases, liver diseases, pancreatic diseases or malignancies, * any neurological diseases or malignancies, * pregnant and lactating mothers, * any metabolic diseases such as hypertension, hypercholesterolaemia, diabetes mellitus, hyper- and hypothyroidism. * known psychiatric diagnoses or/and consume psychotropic drugs, * ongoing electroconvulsive therapy (ect), * consumption of antibiotics, probiotics, prebiotics, symbiotics products, laxatives, antispasmodics, and/or anticholinergics who refuse to consent for participation.

Keywords: irritable bowel syndrome subthreshold depression probiotics ibs subclinical depression
multilevel interventions to increase adherence to lung cancer screening

Conditions: Lung Cancer; Lung Cancer Screening

Summary: screening for lung cancer has the potential for a profound public health benefit. repeat annual screening is necessary for early detection of lung cancer. the investigators will test two interventions which include patient education and reminders to improve adherence to lung cancer screening.

screening for lung cancer has the potential for a profound public health benefit. successful population-based screening requires continuous monitoring to adherence repeat screening in high risk adults to achieve similar results. repeat annual screening is necessary for early detection of lung cancer. baseline or first ldct scans detect prevalent lung cancer, when subsequent screening detects new nodules. however, adherence to screening is low, ranging at 28-38% from centers nationally. the investigators developed two novel, patient-centered interventions to address patient education and offering reminders for on-time screening. to address these goals, the specific aims are to: 1) compare effectiveness of two multilevel interventions relative to usual care in improving (a) rates of adherence to lung cancer screening, (b) patient-centered outcomes; and (c) clinic outcomes; and 2) determine the patient-, clinician-, and system-level factors that influence changes in adherence to inform lung cancer screening programs.

Eligibility criteria:
inclusion criteria: * kpwa members * aged 50-78 years * have a negative screening ldct scan * speak english or spanish * meet us preventive services task force guidelines exclusion criteria: * patients who were previously diagnosed with lung cancer, * patients who have a positive scan, * patients who have an indicator for interpreter services, except for spanish

Keywords: lung cancer low dose ct (ldct) lung cancer screening stepped reminders educational video user centered design stakeholders evaluation qualitative patient partners adherence